NCT00259220 is a Phase 3 clinical trial of erythomycin in Upper Gastrointestinal Bleeding, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT00259220?

NCT00259220 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT00259220?

Interventions in NCT00259220: erythomycin, gastric lavage alone, erythromycine and gastric lavage.

What condition does NCT00259220 study?

NCT00259220 studies Upper Gastrointestinal Bleeding.

Is NCT00259220 still recruiting?

NCT00259220 is currently completed. Last updated 30 September 2008.

Last reviewed 2008-09-30 · How we verify

NCT00259220

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

In Urgency Hight Digestive Haemorrhage : Gastric Preparation for Endoscopy

Completed Phase 3 Last updated 30 September 2008

What this trial tests

Phase 3 trial testing erythomycin in Upper Gastrointestinal Bleeding in 270 participants. Completed in 1 August 2008.

Timeline

1 December 2005

Primary endpoint
1 August 2008

1 August 2008

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	270
Start date	1 December 2005
Primary completion	1 August 2008
Estimated completion	1 August 2008
Sites	1 location across France

Drugs / interventions tested

erythomycin — full drug profile →
gastric lavage alone
erythromycine and gastric lavage

Conditions studied

Upper Gastrointestinal Bleeding — all drugs for Upper Gastrointestinal Bleeding →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with Upper Gastrointestinal Bleeding. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Endoscopic yield
Time frame: at the beggining of the study

Sponsor's own description

Gastric lavage is usually used for gastric preparation before endoscopy in patients with upper gastrointestinal bleeding. However, the benefit-risk balance of putting a nasogastric tube in these patients is not clearly defined. This randomized trial is aimed to determine if the use of erythromycin IV before endoscopy could avoid to put a gastric tube for the management of upper gastrointestinal bleeding.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage.
Adão D, Gois AF, Pacheco RL, Pimentel CF, et al · · 2023 · cited 4× · PMID 36723439 · DOI 10.1002/14651858.cd013176.pub2

Verify or expand the search:

Other recruiting trials for Upper Gastrointestinal Bleeding

Currently open trials in the same condition.

NCT04902248 — OTSC vs. Angiographic Embolization in Patients With Refractory Non-variceal Upper Gastrointestinal Bleeding · NA · recruiting

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00259220 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 30 September 2008

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00259220.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing